Outcome
    Limited

    Berberine for SIBO Prevention

    Berberine appears in herbal antimicrobial protocols with modest comparative-trial support.

    Overview

    Berberine appears in herbal antimicrobial protocols with modest comparative-trial support.

    Verdict

    Insufficient evidence

    How It Works

    Broad antimicrobial activity against gram-positive and gram-negative bacteria in the gut lumen.

    Dosing & Protocol

    Typical dose

    Recommended dose
    500mg two to three times daily under guidance
    Expected timeframe
    2-4 weeks

    Protocol

    studied dose
    500 mg two to three times daily as part of a multi-herb antimicrobial combination, for 4 weeks, in a single comparative treatment study
    evidence note
    Verdict is insufficient - prevention has never been studied
    what happened
    That combination was non-inferior to rifaximin for breath test normalisation in people who already had SIBO. Berberine alone was not isolated, and no trial has tested whether it prevents SIBO recurring
    if you still trial it
    Do it under medical supervision and time-limited, not open-ended
    what actually prevents recurrence
    Addressing the underlying cause - motility disorder, adhesions, hypochlorhydria, opioid use - plus a prokinetic where a gastroenterologist advises it

    Evidence

    What the studies say

    A single comparative trial found herbal antimicrobial combinations non-inferior to rifaximin for breath test normalisation. Berberine's individual contribution was not isolated.

    Rifaximin versus herbal antimicrobials for small intestinal bacterial overgrowth

    Score: 4/10
    2014
    cohort
    n=104

    Chedid V, Dhalla S, Clarke JO +6 more

    Herbal antimicrobials achieved breath-test normalisation in 46% of patients compared with 34% for rifaximin

    View source

    Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth

    Score: 5/10
    2014
    cohort
    n=104

    Chedid V, Dhalla S, Clarke JO +6 more

    Response rate for the herbal therapy group was 46% compared with 34% for the rifaximin group in patients with small intestinal bacterial overgrowth.

    View source

    The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases

    Score: 5/10
    2014
    systematic_review

    Vang S, Longley K, Steer CJ +1 more

    Herbal antimicrobials achieved breath-test normalisation in 46% of patients compared with 34% for rifaximin

    View source

    Safety

    Caveats

    Interacts with many medications via CYP inhibition. Not for pregnancy. Does not address the underlying motility cause.

    Less likely to help if

    People whose recurrence is driven by an untreated motility or structural problem.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.